Sun Pharma to acquire Pola Pharma

28-Nov-2018 - Sun Pharmaceutical Industries Ltd. announced that Sun Pharma has entered into a definitive agreement to acquire Pola Pharma Inc. (“Pola Pharma”), a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. The ...

Sun Pharma & NIV sign agreement to fight Zika, Chikungunya and Dengue

27-Jun-2017 - Sun Pharma and The National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare , New Delhi announced that they have signed an agreement for testing phytopharmaceutical, biologic and ...

Sun Pharma & Moebius Medical sign exclusive global licensing deal

Dela contains development of novel liposomal non-opiod pain product for osteoarthritis

13-Dec-2016 - Sun Pharma and Israel-based Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis. MM-II is a novel non-opioid product that leverages the physical properties of proprietary ...

Sun Pharma Receives USFDA Approval For BromSite™

13-Apr-2016 - Sun Pharma announced that one of its wholly owned subsidiaries has received approval from USFDA for its New Drug Application (NDA) related to BromSite™ (bromfenac ophthalmic solution) 0.075% for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing ...

Sun Pharma successfully acquires InSite Vision

04-Nov-2015 - Sun Pharmaceutical Industries Ltd. announced the successful completion of its acquisition of InSite Vision Incorporated. The acquisition was completed by means of a short-form merger under Delaware law. Post the short-form merger, InSite has become an indirect wholly owned subsidiary of Sun ...

Sun Pharma to acquire InSite Vision

18-Sep-2015 - Sun Pharmaceutical Industries Ltd. announced that one of its subsidiary has entered into an agreement and plan of merger with InSite Vision Inc. (InSite Vision) under which a Sun Pharma subsidiary has offered to acquire InSite Vision. InSite Vision focuses on developing new specialty ophthalmic ...

Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs

17-Apr-2015 - Sun Pharmaceutical Industries Ltd. and the Technion – Israel institute of technology announced that their respective subsidiaries have entered into an exclusive worldwide research and license agreement. This agreement aims at the development of a joint project, based on new findings by Nobel ...

Sun Pharma announces closure of merger deal with Ranbaxy

26-Mar-2015 - Sun Pharmaceutical Industries Ltd. begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth. The merger has fortified Sun Pharma’s position as the world’s fifth ...

Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta

30-Nov-2010 - Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride ...

U.S. District Court Rules Against Lilly Regarding Gemzar Patent

Lilly Plans Appeal to Defend Gemzar's Intellectual Property

18-Aug-2009 - Eli Lilly and Company announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment. The Court's ruling invalidates Lilly's '826 patent, or method-of-use patent, for Gemzar((R)) (gemcitabine HCl for injection) ...